A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection IND-enabling studies underway, with Phase I study initiation expected in 2Q26 Webcast and conference call to be held today at 4:30 pm ET NEWARK,... Read More

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and... Read More

NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference taking place June 3-5, 2025, in New York, NY. The Company will also participate in one-on-one meetings. Jefferies Global Healthcare Conference - June 3-5,... Read More

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill PN-881, a first-in-class oral peptide targeting the IL-17 pathway, potently and selectively binds IL-17A... Read More

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1 st Conference call to be held June 2 nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD... Read More

NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2025. Presentation Details: Presenting Author: Andrew T. Kuykendall, M.D. (Moffitt Cancer Center) Title: Results From VERIFY, a Phase 3,... Read More

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in accordance with the terms of... Read More

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously NEWARK, CA / ACCESS Newswire / April 10, 2025 / Protagonist Therapeutics, Inc.... Read More

Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CALIFORNIA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced its inclusion in Fast Company's prestigious annual list of the World's Most Innovative Companies... Read More

Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28 All three doses met the primary endpoint of clinical response at Week 12, with a favorable safety profile These results in ulcerative colitis build on strong data recently reported for the plaque psoriasis Phase 3 program NEWARK, CALIFORNIA / ACCESS Newswire / March 10,... Read More

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from Phase 3 ICONIC-ADVANCE 1&2studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsO Results pave the way to initiate the first-ever head-to-head study (ICONIC-ASCEND)... Read More

$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025 PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024 Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025 Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative... Read More

NEWARK, CALIFORNIA / ACCESS Newswire / January 29, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company")will host an in-person and virtual investor event on Thursday, February 6, 2025, at 10:30 AM ET in New York. To register, click here. The event will feature key opinion leader (KOL) insights from Andrew Kuykendall, MD (Moffitt Cancer Center) and Joseph Michael Scandura, MD, PhD (Weill Cornell Medicine),... Read More

NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 12-16, 2025 in San Francisco, CA. The Company will also participate in one-on-one meetings. 43rd Annual J.P. Morgan Healthcare... Read More

54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and improvements in patient-reported outcomes in patients with polycythemia vera NEWARK, CA / ACCESSWIRE / December 9, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from a poster presentation with final data from the rusfertide Phase 2 REVIVE... Read More

NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference taking place December 3-5, 2024 in Coral Gables, Florida. The Company will also participate in one-on-one meetings. 7th Annual Evercore ISI... Read More

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) IND enabling studies underway, with Phase I initiation expected in Q425 Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of... Read More

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study... Read More

ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 ICONIC-TOTAL achieved its primary endpoint of IGA score of 0 or 1 at week 16 in patients with plaque psoriasis in difficult-to-treat areas Protagonist has earned a $165 million milestone under the terms of recently amended agreement, inclusive of $50 million in... Read More

Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025 Top line results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in Q1 2025 Development candidate nomination for oral... Read More

NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66 th Annual American Society of Hematology (ASH) Annual Meeting being held in San Diego from December 7-10, 2024. ASH Presentation Details: Presenting author: Aaron Gerds, MD... Read More

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock... Read More

NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY. H.C. Wainwright 26th Annual Global Investment Conference - September 9-11, 2024... Read More

JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in moderate-to-severe plaque psoriasis expected to complete the primary endpoint portion of the studies in Q4 2024 JNJ-2113 Phase 2b ANTHEM clinical trial in moderate-to-severe ulcerative colitis expected to complete the primary endpoint portion of the study in Q4 2024 Rusfertide Phase 2 REVIVE study long-term follow-up data in polycythemia vera presented... Read More

NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE . JNJ-2113 is the first- and only-in-class targeted oral peptide... Read More

Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D.... Read More

NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the BTIG Virtual Biotechnology Conference. BTIG Virtual Biotechnology Conference - August 5-6, 2024 Format: Fireside Chat Day/Time: Tuesday, August 6 at... Read More

Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Patients receiving rusfertide in the open-label extension of the REVIVE study are eligible to roll over to the THRIVE study for an additional 2 years of treatment NEWARK, CA / ACCESSWIRE / June 14, 2024 /... Read More

NEWARK, CA / ACCESSWIRE / May 31, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York City on June 4-6, 2024. Jefferies Global Healthcare Conference Format: Fireside Chat Day/Time: Wednesday, June... Read More

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Association (EHA) Congress being held in Madrid, Spain from June 13-16, 2024. There will also be a published abstract showing the absence of... Read More

Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027 [1] Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis is now complete Data from the Phase 2b FRONTIER 2, a 52-week long term extension study of JNJ-2113 presented at the American Academy of Dermatology 2024 Annual Meeting in March... Read More

NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and investor meetings at the Citizens JMP Life Sciences Conference being held in New York City on May 13-14, 2024. Also, Dr. Patel will join a panel at the Capital One 1st Annual... Read More

On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced it has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera ("PV") as of today and expects to meet the... Read More

NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024 . Closing of the transaction was contingent on completion of review under the Hart-Scott-Rodino (HSR) Antitrust... Read More

Long-term extension (LTE) FRONTIER 2 study demonstrated sustained efficacy and similar safety results from Week 16 to Week 52, consistent with previously reported FRONTIER 1 16-week Phase 2b study The proportion of patients achieving PASI 75, 90 and 100 response rates at Week 16 were maintained through Week 52, confirming the durability of response 59.5% and 64.3% of patients in the highest dose group (100 mg BID) achieved a... Read More

NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences: Event: 2024 Jefferies Biotech on the Bay Summit Date: March 12-13, 2024 Location: W Hotel South Beach, Miami, FL. Event: 13 th Annual Napa Valley Biotech Forum Date: March 26-28, 2024 Presentation: Tuesday, March 26 at 10:30-11:10 A.M. PDT... Read More

Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway extended through Q4 2027[1] Two articles published in the New England Journal of Medicine reporting results from the Phase 2b FRONTIER 1 study of JNJ-2113 and the Phase 2 REVIVE study of rusfertide Our Partner, Johnson & Johnson... Read More

Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy Rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assessed by the Myeloproliferative Neoplasm Symptom Assessment Form REVIVE is one of two pivotal studies, including an ongoing Phase 3 study,... Read More

NEWARK, CA / ACCESSWIRE / February 20, 2024 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on February 15, 2024, it issued inducement awards to Sid Reddy, the Company's recently hired Vice President and Controller, in accordance with the terms of Mr. Reddy's employment offer letter. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29,... Read More

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial evaluating... Read More

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV) Takeda Will Make an Upfront Payment of $300 Million at Closing Partnership Combines Protagonist's Leadership in Pharmaceutical... Read More

NEWARK, CA / ACCESSWIRE / January 29, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference being held in New York City on February 7-8, 2024. Event: 6th Annual Guggenheim Healthcare Talks Annual Biotechnology... Read More

NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a presentation and host one-on-one meetings with investors at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8-11, 2024. Event: 42nd Annual J.P. Morgan Healthcare... Read More

NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis. With this additional payment, the... Read More

Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Analysis of PACIFIC Phase 2 study shows that rusfertide improves markers of iron deficiency in patients with polycythemia vera Prevalence of thromboembolic events and secondary cancers in polycythemia vera presented based on a... Read More

The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1 Protagonist eligible to receive $115 million milestone upon achieving the co-primary endpoints in any one of the studies NEWARK, CA / ACCESSWIRE / November 27, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced two additional Phase 3 studies,... Read More

NEWARK, CA / ACCESSWIRE / November 16, 2023 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2023, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February... Read More

NEWARK, CA / ACCESSWIRE / November 9, 2023 / Protagonist Therapeutics (Nasdaq:PTGX) today announced it ranked in the top 3% of the 2023 Deloitte Technology Fast 500 TM , a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. Life sciences and software companies dominated at the top of the Fast 500 this year; Protagonist joins Vir Biotechnology... Read More

Five rusfertide abstracts accepted for oral and poster presentations at the 65 th ASH Annual Meeting and Exposition (ASH2023) Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral IL-23 receptor antagonist peptide drug candidate for moderate-to-severe plaque psoriasis presented in July 2023 JNJ-2113 clinical development program advances with two Phase 3... Read More

Two oral presentations and three poster presentations elucidate new data relevant to rusfertide, a hepcidin mimetic with potential therapeutic value in the treatment of Polycythemia Vera and other disease indications NEWARK, CA / ACCESSWIRE / November 2, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that five abstracts relevant to the Company's rusfertide program have... Read More

NEWARK, CA / ACCESSWIRE / November 1, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the achievement of a $50 million milestone event under its license and collaboration agreement with Janssen Biotech, Inc., a Johnson & Johnson company ("Janssen"). The milestone was earned when the third patient was dosed in the ICONIC TOTAL Phase 3 clinical study of JNJ-2113 in patients with... Read More

NEWARK, CA / ACCESSWIRE / November 1, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in presentations and host one-on-one meetings with investors at the following investor conferences this month: Event: Guggenheim 5th Annual I&I Conference Date: November 6, 2023 Fireside Chat: November 6,... Read More

NEWARK, CA / ACCESSWIRE / October 30, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Daniel N. Swisher, Jr. to its Board of Directors. Mr. Swisher recently retired as President and Chief Operating Officer of Jazz Pharmaceuticals, a position he held since 2018. Commenting on this appointment, Mr. Swisher remarked, "I am honored to join the Board of Directors... Read More

ICONIC Phase 3 clinical program initiation in adults with moderate to severe plaque psoriasis ANTHEM Phase 2b initiation in ulcerative colitis Company is eligible to receive next two milestone payments for a total of $60M NEWARK, CA / ACCESSWIRE / October 9, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that the company will be eligible to receive $60M in milestone... Read More

NEWARK, CA / ACCESSWIRE / October 3, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on September 29, 2023, it issued inducement awards to Katharina Modelska, M.D., Ph.D., the Company's recently hired Senior Vice President, Clinical Development, in accordance with the terms of Dr. Modelska's employment offer letter. The awards were granted under the Protagonist Therapeutics Amended and Restated... Read More

NEWARK, CA / ACCESSWIRE / September 5, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in fireside chat presentations and host one-on-one meetings at the Wells Fargo and H.C. Wainwright investor conferences in September. Details are as follows: Wells Fargo 2023 Healthcare Conference,... Read More

NEWARK, CA / ACCESSWIRE / August 16, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on August 15, 2023, it issued inducement awards to Christine Rocha, the Company's recently hired Vice President, Clinical Operations, in accordance with the terms of Ms. Rocha's employment offer letter. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted... Read More

Estimated cash runway now extended through Q1 2026 NEWARK, CA / ACCESSWIRE / August 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has received approximately $34.4 million in proceeds from the exercise of warrants to purchase 2.75 million shares of the Company's Common Stock. The warrants were issued in connection with an August 2018 equity financing and expired on August... Read More

Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor antagonist oral peptide drug candidate for the treatment of moderate-to-severe plaque psoriasis, presented at the World Congress of Dermatology. JNJ-2113 now advances toward a Phase 3 study in moderate-to-severe psoriasis and a Phase 2b study in ulcerative colitis. Positive data from the randomized... Read More

NEWARK, CA / ACCESSWIRE / July 18, 2023 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 17, 2023, it issued inducement awards to Peter Morello, Ph.D. the Company's recently hired Vice President, Medical Communications and Publication Planning, in accordance with the terms of Dr. Morello's employment offer letter. The awards were granted under the Protagonist Therapeutics Amended and Restated... Read More

Phase 2b FRONTIER 1 data presentation at World Congress of Dermatology highlights that a greater proportion of patients achieved 75, 90 and 100 percent improvement in skin clearance at week 16 in comparison to placebo Phase 3 development in moderate-to-severe plaque psoriasis and Phase 2b development in ulcerative colitis are planned by Janssen NEWARK, CA / ACCESSWIRE / July 4, 2023 / Protagonist Therapeutics, Inc.... Read More

NEWARK, CA / ACCESSWIRE / June 9, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai, provided a press briefing this morning on the late-breaking oral presentation abstract LB2710 : Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide - Blinded Randomized... Read More

NEWARK, CA / ACCESSWIRE / June 6, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that a late-breaking abstract featuring blinded, randomized withdrawal data from the rusfertide (PTG-300) REVIVE Phase 2 study in polycythemia vera (PV) has been accepted for oral presentation at the European Hematology Association (EHA) 2023 Congress: Targeted Therapy of Uncontrolled... Read More

NEWARK, CA / ACCESSWIRE / June 1, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the Jefferies Healthcare Conference taking place June 7-9, 2023, in New York, New York. Presentation Details: Event: Jefferies... Read More

Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases NEWARK, Calif. , May 12, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) , on Phase 1 and preclinical studies of JNJ-2113 (formerly... Read More

NEWARK, Calif. , May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the JMP Securities Life Sciences Conference, an investor event taking place May 15-16, 2023 in New York, New York.... Read More

NEWARK, Calif. , May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that additional data from the REVIVE study of rusfertide in polycythemia vera will be presented in two posters at the annual Congress of the European Hematology Association (EHA), taking place June 8-11, 2023 in Frankfurt, Germany and virtually through June 15, 2023 . Details are as follows:... Read More

Announced positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), a first-in-class oral peptide for the treatment of moderate-to-severe plaque psoriasis; additional data to be shared at medical conferences beginning in Q2 2023 Announced positive topline results from the randomized withdrawal portion of the Phase 2 REVIVE study of rusfertide in polycythemia vera (PV), with additional data to... Read More

NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share. Gross proceeds to Protagonist from the offering are expected to be $100 million, before deducting underwriting discounts and commissions and... Read More

NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the securities to be sold in the offering are being offered by Protagonist. In addition, Protagonist expects to grant the underwriters a 30-day option to purchase up to an additional $15... Read More

Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically significant results from the randomized withdrawal portion of the REVIVE study of rusfertide in polycythemia vera, achieving its primary endpoint of proportion of responders on rusfertide versus placebo (p=0.0003) NEWARK, CA /... Read More

Rusfertide met the study's primary endpoint, with a statistically significant higher number of responders on rusfertide versus placebo (p=0.0003) Rusfertide continues to be generally well tolerated with no new safety signals NEWARK, CA / ACCESSWIRE / March 15, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company"), today announced positive topline results from the blinded, placebo-controlled,... Read More

JNJ-2113 (formerly PN-235) met the study's primary endpoint, with a statistically significantly higher proportion of adult patients with moderate-to-severe plaque psoriasis achieving PASI-75 in all treatment groups at Week 16 compared to placebo Treatment was well tolerated, with no meaningful difference in frequency of adverse events across treatment groups NEWARK, Calif. , March 7, 2023 /PRNewswire/ -- Protagonist... Read More

NEWARK, Calif. , Dec. 21, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will offer a corporate presentation and host one-on-one meetings with investors at the 41 st Annual J.P. Morgan Healthcare Conference, taking place January 9-12 in San Francisco, California . Presentation Details:... Read More

NEWARK, Calif. , Dec. 1, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the JMP Securities Hematology and Oncology Summit, a virtual investor event taking place December 6-7, 2022 . Presentation... Read More